Literature DB >> 17225936

Hyperdiploidy defines a distinct cytogenetic entity of meningiomas.

Ralf Ketter1, Yoo-Jin Kim, Simone Storck, Jörg Rahnenführer, Bernd F M Romeike, Wolf-Ingo Steudel, Klaus D Zang, Wolfram Henn.   

Abstract

BACKGROUND: The most common chromosomal aberration found in meningiomas is monosomy 22. Progression and recurrence of meningiomas are usually associated with additional chromosome losses. Rarely, however, meningiomas have strongly hyperdiploid karyotypes with over 50 chromosomes; the objective of this study was to explore the cytogenetic and histopathologic patterns as well as the clinical significance of hyperdiploidy in meningiomas.
METHODS: Within a series of 677 consecutive meningiomas, we identified a subgroup comprising 16 cases that display a strikingly uniform pattern of hyperdiploidy mostly without structural chromosome rearrangements, as shown by banding techniques and, in the single structurally aberrant case, spectral karyotyping.
RESULTS: These meningiomas each have between 50 and 56 chromosomes, with trisomy 12 (14/16 cases), trisomy 20 (13/16 cases), trisomy 5 (12/16 cases), and trisomy 17 (10/16 cases). Histomorphologically, hyperdiploid meningiomas feature a heterogeneous phenotype. However, they are associated with a higher histological grade, and decreased expression of alkaline phosphatase as compared to meningiomas with typical karyotype. In two patients, recurrences were documented and three patients died of disease during the period of observation, indicating a worse prognosis of hyperdiploid than of cytogenetically typical meningiomas.
CONCLUSION: We conclude that hyperdiploidy constitutes a small but clinically relevant entity of biologically aggressive meningiomas, which are cytogenetically distinguishable from the majority of common-type meningiomas.

Entities:  

Mesh:

Year:  2007        PMID: 17225936     DOI: 10.1007/s11060-006-9318-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

1.  The recurrence of intracranial meningiomas after surgical treatment.

Authors:  D SIMPSON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1957-02       Impact factor: 10.154

2.  Mtreemix: a software package for learning and using mixture models of mutagenetic trees.

Authors:  Niko Beerenwinkel; Jörg Rahnenführer; Rolf Kaiser; Daniel Hoffmann; Joachim Selbig; Thomas Lengauer
Journal:  Bioinformatics       Date:  2005-01-18       Impact factor: 6.937

3.  Learning multiple evolutionary pathways from cross-sectional data.

Authors:  Niko Beerenwinkel; Jörg Rahnenführer; Martin Däumer; Daniel Hoffmann; Rolf Kaiser; Joachim Selbig; Thomas Lengauer
Journal:  J Comput Biol       Date:  2005 Jul-Aug       Impact factor: 1.479

4.  Interphase cytogenetics: a new tool for the study of genetic changes in brain tumors.

Authors:  E P Arnoldus; L B Wolters; J H Voormolen; S G van Duinen; A K Raap; M van der Ploeg; A C Peters
Journal:  J Neurosurg       Date:  1992-06       Impact factor: 5.115

5.  Lack of alkaline phosphatase activity predicts meningioma recurrence.

Authors:  Corinne Bouvier; Agnès Liprandi; Carole Colin; Roch Giorgi; Benoit Quilichini; Philippe Metellus; Dominique Figarella-Branger
Journal:  Am J Clin Pathol       Date:  2005-08       Impact factor: 2.493

6.  Application of long-term collagenase disaggregation for the cytogenetic analysis of human solid tumors.

Authors:  J Limon; P Dal Cin; A A Sandberg
Journal:  Cancer Genet Cytogenet       Date:  1986-12

7.  Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions?

Authors:  José María Sayagués; María Dolores Tabernero; Angel Maíllo; Ana Espinosa; Ana Rasillo; Pedro Díaz; Juana Ciudad; Antonio López; Marta Merino; Jesús María Gonçalves; Angel Santos-Briz; Francisco Morales; Alberto Orfao
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

8.  Estimating cancer survival and clinical outcome based on genetic tumor progression scores.

Authors:  Jörg Rahnenführer; Niko Beerenwinkel; Wolfgang A Schulz; Christian Hartmann; Andreas von Deimling; Bernd Wullich; Thomas Lengauer
Journal:  Bioinformatics       Date:  2005-02-10       Impact factor: 6.937

9.  Intratumorous heterogeneity of chromosome 10 and 17 in meningiomas using non-radioactive in situ hybridization.

Authors:  M Scholz; J Gottschalk; E Striepecke; R Firsching; A Harders; L Füzesi
Journal:  J Neurosurg Sci       Date:  1996-03       Impact factor: 2.279

10.  Allelic loss at 1p is associated with tumor progression of meningiomas.

Authors:  M J Bello; J M de Campos; M E Kusak; J Vaquero; J L Sarasa; A Pestaña; J A Rey
Journal:  Genes Chromosomes Cancer       Date:  1994-04       Impact factor: 5.006

View more
  8 in total

1.  Distinct clinical outcome of microcystic meningioma as a WHO grade 1 meningioma subtype.

Authors:  Leihao Ren; Lingyang Hua; Zhongyuan Bao; Hiroaki Wakimoto; Ye Gong; Jiaojiao Deng; Daijun Wang; Jiawei Chen; Hong Chen; Tareq A Juratli
Journal:  J Neurooncol       Date:  2022-05-25       Impact factor: 4.130

Review 2.  Genetic/molecular alterations of meningiomas and the signaling pathways targeted.

Authors:  Patrícia Domingues; María González-Tablas; Álvaro Otero; Daniel Pascual; Laura Ruiz; David Miranda; Pablo Sousa; Jesús María Gonçalves; María Celeste Lopes; Alberto Orfao; María Dolores Tabernero
Journal:  Oncotarget       Date:  2015-05-10

3.  Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5.

Authors:  Malak S Abedalthagafi; Parker H Merrill; Wenya Linda Bi; Robert T Jones; Marc L Listewnik; Shakti H Ramkissoon; Aaron R Thorner; Ian F Dunn; Rameen Beroukhim; Brian M Alexander; Priscilla K Brastianos; Joshua M Francis; Rebecca D Folkerth; Keith L Ligon; Paul Van Hummelen; Azra H Ligon; Sandro Santagata
Journal:  Oncotarget       Date:  2014-11-15

4.  Identification of shared genomic aberrations between angiomatous and microcystic meningiomas.

Authors:  Yasuhiro Kuroi; Hiroyuki Akagawa; Makoto Shibuya; Hideaki Onda; Tatsuya Maegawa; Hidetoshi Kasuya
Journal:  Neurooncol Adv       Date:  2019-09-28

5.  Deletions in the 17q chromosomal region and their influence on the clonal cytogenetic evolution of recurrent meningiomas.

Authors:  Sina Hemmer; Steffi Urbschat; Joachim Oertel; Ralf Ketter
Journal:  Mol Cytogenet       Date:  2019-05-24       Impact factor: 2.009

6.  Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.

Authors:  Priscilla K Brastianos; Peleg M Horowitz; Sandro Santagata; Robert T Jones; Aaron McKenna; Gad Getz; Keith L Ligon; Emanuele Palescandolo; Paul Van Hummelen; Matthew D Ducar; Alina Raza; Ashwini Sunkavalli; Laura E Macconaill; Anat O Stemmer-Rachamimov; David N Louis; William C Hahn; Ian F Dunn; Rameen Beroukhim
Journal:  Nat Genet       Date:  2013-01-20       Impact factor: 38.330

7.  Establishment of a molecular cytogenetic analysis for native tumor tissue of meningiomas-suitable for clinical application.

Authors:  Cornelia Lerner; Ralf Ketter; Stefan Linsler; Wolfram Henn; Joachim Oertel; Steffi Urbschat
Journal:  Mol Cytogenet       Date:  2014-02-05       Impact factor: 2.009

8.  Molecular biological determinations of meningioma progression and recurrence.

Authors:  Stefan Linsler; Dennis Kraemer; Christina Driess; Joachim Oertel; Kai Kammers; Jörg Rahnenführer; Ralf Ketter; Steffi Urbschat
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.